ARS Pharmaceuticals Inc (SPRY) Q3 2026 Earnings Call Highlights: neffy Market Share Tops 5% as ...
Cantor Fitzgerald Maintains Overweight on ARS Pharmaceuticals, Lowers Price Target to $20
ARS Pharmaceuticals: Lawsuits And Cash Burn Are Priced In, Yet The Stock Keeps Falling
ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy
Loading...